Picture of Nykode Therapeutics ASA logo

NYKD — Nykode Therapeutics ASA News Story

0.000.00%
no flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapMomentum Trap

Brief: Nykode Therapeutics: mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy

June 11 (Reuters) - Nykode Therapeutics ASA  NYKD.OL :
    * NYKODE THERAPEUTICS ANNOUNCES MRNA-LNP CANCER VACCINE
DEMONSTRATES SUPERIOR EFFICACY
    * LATEST STUDY DEMONSTRATED THAT APC-TARGETED VACCINE
CONSISTENTLY
ACHIEVED BROADER AND MORE ROBUST IMMUNE RESPONSE ACROSS DOSES
COMPARED TO UNTARGETED NEOANTIGEN VACCINE

Source text for Eikon:  ID:nObiCZYMXa 
Further company coverage:  NYKD.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Recent news on Nykode Therapeutics ASA

See all news